大容量注射剂

Search documents
海南双成药业股份有限公司关于取得换发的《药品生产许可证》的公告
Zhong Guo Zheng Quan Bao - Zhong Zheng Wang· 2025-08-20 19:53
Core Points - The company, Hainan Shuangcheng Pharmaceutical Co., Ltd., has received a renewed Drug Production License from the Hainan Provincial Drug Administration, ensuring its continued operations [1][2][3] - The previous license was set to expire on November 5, 2025, and the new license is valid until August 7, 2030 [1] - The company specializes in the production of small-volume injectables, lyophilized powder injections, raw materials, and large-volume injectables [1] Company Information - Company Name: Hainan Shuangcheng Pharmaceutical Co., Ltd. [1] - Registered Address: No. 16, Xingguo Road, Xiuying District, Haikou City [1] - Legal Representative: Wang Chengdong [1] - Quality Responsible Person: Li Yuan [1] - License Number: Qiong 20150028 [1] - Daily Supervision Management Agency: Hainan Provincial Drug Administration [1] License Details - The new Drug Production License was issued due to the impending expiration of the previous license [1] - The renewal of the license is expected to have no significant impact on the company's production and operations [1]
江西省药品生产监督检查结果公告(2025年第1号)
Zhong Guo Zhi Liang Xin Wen Wang· 2025-07-25 07:57
Core Viewpoint - The article discusses the results of drug production supervision inspections conducted by the Jiangxi Provincial Drug Supervision Administration from January to June 2025, highlighting compliance and non-compliance among various pharmaceutical companies [2][3][4]. Summary by Category Inspection Results - A total of 23 pharmaceutical companies were inspected during the first half of 2025, with most companies found to be compliant with the Good Manufacturing Practice (GMP) standards [2][3]. - Specific companies such as Jiangxi Ma Kang Pharmaceutical Co., Ltd. and Jiangxi Chengzhi Yongfeng Pharmaceutical Co., Ltd. were noted for their compliance in producing various drug forms including eye drops and traditional Chinese medicine [2][3]. Compliance Details - Companies like Jiangxi Qinfeng Pharmaceutical Co., Ltd. and Jiangxi Yichuan Pharmaceutical Technology Co., Ltd. were recognized for their adherence to GMP during inspections, covering a range of products from small volume injections to tablets [3][4]. - The inspections included checks on production lines for specific drugs, ensuring that companies met the required safety and quality standards [2][3]. Non-Compliance Issues - Some companies faced issues during inspections, although the article primarily focuses on those that complied with regulations [2][3]. - The inspections aimed to ensure that all pharmaceutical products manufactured in the province meet the necessary legal and quality standards [2][3][4].
北陆药业: 公司章程
Zheng Quan Zhi Xing· 2025-05-22 12:26
Group 1 - The company is established as a joint-stock company in accordance with the Company Law and other relevant regulations [2][3] - The registered capital of the company is RMB 491,855,896 [3] - The company was approved by the China Securities Regulatory Commission to issue 17 million shares of ordinary stock to the public in 2009 [2][3] Group 2 - The company's business scope includes the production and sale of large-volume injections, small-volume injections, tablets, granules, and raw materials [4][5] - The company aims to leverage its technological advantages and high-tech talent resources to provide high-quality pharmaceutical products and services [4] Group 3 - The company has a share structure consisting of ordinary shares, with a total of 491,855,896 shares issued [8] - The shares are issued at a par value of RMB 1 per share [8] Group 4 - The company’s shareholders have the right to receive dividends and participate in decision-making processes at the shareholders' meetings [12][13] - Shareholders holding more than 5% of the shares are subject to specific trading restrictions [10][11] Group 5 - The company’s board of directors is responsible for major decisions, and shareholders have the right to request the convening of shareholder meetings under certain conditions [20][23] - The company must disclose information regarding significant transactions and decisions to ensure transparency [42][43]